Novo’s GLP-1s Highlight List as CMS Unveils Final Prices For Second Cycle of Drug Negotiations

The discounts should be compared against the drugs’ “ultimate net price” rather than their indicated list price to gauge the true impact of the negotiations, BMO Capital Markets analysts said.